image credit: Unsplash

Servier Acquires Cancer Biotech Symphogen

Servier has entered into a definitive agreement to acquire the antibody discovery biotech Symphogen A/S. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-development platform is fully utilized.

Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

Following completion of the acquisition, Symphogen will become Servier’s antibody center of excellence for its therapeutic areas.

Read More on Contract Pharma